<DOC>
	<DOC>NCT01505881</DOC>
	<brief_summary>To collect additional data relating to safety and indicators of efficacy for patients who have participated in the 1160.113 study.</brief_summary>
	<brief_title>Follow on Study From RE-ALIGN</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criteria: 1. Completed study 1160.113 per protocol 2. Continuing need for anticoagulation Exclusion criteria: 1. uncontrolled hypertension 2. severe renal impairment 3. active liver disease 4. increased risk of bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>